Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Recognition of Healthcare Burden: There is an ever-increasing awareness that treating obesity results in meaningful improvement in cardiovascular outcomes and lowers the risk of developing multiple related cardiometabolic diseases including Type 2 Diabetes Mellitus (T2DM), chronic kidney disease (CKD), heart failure, fatty liver or MASH, obstructive sleep apnea (OSA), and peripheral arterial disease (PAD), moving the needle beyond aesthetics and towards total health improvement
Abstract Background A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM)
10.3390/md14080148 69 GundermannK.BchelC
Acknowledgements This work was supported by the Canadian Institutes of Health Research (CIHR
Discover the Solution The Solution Glutathione Your Skin's Master Antioxidant LumeniX delivers glutathione the body's most powerful antioxidant using patented WaferiX sublingual technology
:max_bytes(150000):strip_icc()/VWH-MiraNorian-WeightLossDrugUpdate-4000x2700-c813fa5051604eec9c136047fb44d23a.png)
